Cellectis News

News

Ticker

ALCLS.PA

ISIN

FR0010425595

Chiffre d'affaires Résultat net P/E P/S EBIT Dividende Achats de membres du conseil Actions Capitalisation boursière Endettement Passifs Capitaux propres AAQS Effectifs ROE ROA ROCE News Documents

Actualités Eulerpool Cellectis

23/10/2024 16:15:57

Cellectis SA: Revolutionäre Fortschritte in der Gen-Editierung auf dem ESGCT-Kongress

Actualités de l'action Cellectis

Cellectis est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Cellectis.

20 mars·
SeekingAlpha
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
11 février·
Yahoo
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading
9 février·
Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
23 janvier·
Yahoo
European Penny Stocks To Watch: Market Caps Over €100M
22 décembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
18 décembre·
SeekingAlpha
Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This
12 décembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
1 décembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
26 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
21 novembre·
Yahoo
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
20 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
19 novembre·
Benzinga
Cellectis Boosts Gene Editing Efficiency With New Non-Viral DNA Breakthrough in Stem Cells
14 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
11 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
11 novembre·
Yahoo
European Penny Stocks To Watch: AFYREN SAS Leads The Pack
10 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading
7 novembre·
Yahoo
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
7 novembre·
Yahoo
Monthly information on share capital and company voting rights
7 novembre·
Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Down Modestly for Week
31 octobre·
Yahoo
Cellectis to Report Third Quarter Financial Results on November 7, 2025

Communiqués de presse relatifs à l'action Cellectis

Cellectis publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

3 mars•
Cellectis
Cellectis Posts Quarterly Loss Per Share Of $0.55
5 janvier•
Cellectis
Cellectis Extends Cash Runway Into 2024
18 novembre•
Cellectis
Cytovia And Cellectis Expand Their Talen Gene-Edited Ink Partnership To Enable Broader Collaboration In China
12 novembre•
Cellectis
Cellectis Presents First Preclinical Data On Ucartmeso To Treat Solid Tumors
5 novembre•
Cellectis
Cellectis Q3 Net Loss Widens At $40.1 Million
4 novembre•
Cellectis
Cellectis Provides Business Update, Reports Results For Q3
5 août•
Cellectis
Cellectis SA QTRLY Total Revenues And Other Income $14.6 Million Versus $4.6 Million
15 juin•
Cellectis
Cellectis Announces New Product Development, Genome Surgey Platfom
6 mai•
Cellectis
Cellectis SA Says Qtrly Loss Per Share $0.28
6 mai•
Cellectis
Cellectis Posts Quarterly EPS Of $0.47
4 mars•
Cellectis
Cellectis Says Q4 Loss Per Share $0.95
16 février•
Cellectis
Cytovia Therapeutics And Cellectis Partner To Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
16 décembre•
Cellectis
Cellectis Announces Withdrawal Of Follow-On Offering
14 décembre•
Cellectis
Cellectis Announces Launch Of Follow-On Offering
18 novembre•
Cellectis
Cellectis Says FDA Lifts Clinical Hold On Melani-01 Study Evaluating Cellectis' Product Candidate Ucartcs1 In Multiple Myeloma
6 novembre•
Cellectis
Cellectis Q3 Consolidated Net Loss Attributable To Shareholders Widens To 30 Million Dollars
16 octobre•
Cellectis
Calyxt Announces 15 Million Dollars Registered Direct Offering
6 août•
Cellectis
Cellectis Q2 Net Loss Narrows To 35.9 Million Dollars
6 juillet•
Cellectis
Cellectis SA Says Melani-01 Trial Has Been Placed On Clinical Hold By U.S. FDA
6 mai•
Cellectis
Cellectis Says Q1 Adjusted Earnings Per Share $0.57
4 mars•
Cellectis
Cellectis Says Quarterly Consolidated Revenues And Other Income Were $6 Mln Versus $3 Mln
18 février•
Cellectis
Cellectis And Servier Announces Execution Of Binding Term Sheet To Enter Amendment To Agreement Signed In 2014

Cellectis News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Cellectis (ALCLS.PA, ISIN : FR0010425595). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Cellectis.

Cellectis Action

Cellectis Cellectis SA est une entreprise de biotechnologie émergente qui se concentre sur le développement de thérapies innovantes pour le cancer et d'autres maladies graves. L'entreprise a été fondée en 1999 par un scientifique français nommé André Choulika et a son siège à Paris, en France.